Long-term safety and efficacy of paclitaxel-eluting stents: Final 5-year analysis from the TAXUS clinical trial program

JACC: Cardiovascular Interventions

Volumn 4, Issue 5, 2011, Pages 530-542

  Stone, Gregg W ^a,b   Ellis, Stephen G ^c   Colombo, Antonio ^d   Grube, Eberhard ^e   Popma, Jeffrey J ^f   Uchida, Takahiro ^g   Bleuit, Jill S ^g   Dawkins, Keith D ^g   Russell, Mary E ^g  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e ELISABETH KRANKENHAUS ESSEN   (Germany)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g BOSTON SCIENTIFIC CORPORATION   (United States)

Author keywords

bare metal stent(s); drug eluting stent(s); myocardial infarction; target lesion revascularization; target vessel revascularization

Indexed keywords

PACLITAXEL;

ADULT; ARTICLE; BARE METAL STENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; STENT THROMBOSIS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DOUBLE-BLIND METHOD; DRUG-ELUTING STENTS; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METALS; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STENTS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 79956277262     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2011.03.005     Document Type: Article

References (30)

1. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42. (Pubitemid 36070930)
2. Grube E, Silber S, Hauptmann KE, et al. Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I). Am J Cardiol 2005;96:79-82. (Pubitemid 40853945)
3. Colombo A, Drzewiecki J, Banning A, et al., for the TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94.
4. Silber S, Colombo A, Banning AP, et al. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Circulation 2009;120:1498-504.
5. Stone GW, Ellis SG, Cox DA, et al., for the TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31. (Pubitemid 38067635)
6. Stone GW, Ellis SG, Cox DA, et al., for the TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109:1942-7.
7. Ellis SG, Stone GW, Cox DA, et al., for the TAXUS-IV Investigators. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel Stent). J Am Coll Cardiol Intv 2009;2:1248-59.
8. Stone GW, Ellis SG, Cannon L, et al., for the TAXUS V Investigators. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294:1215-23.
9. Grube E, Dawkins KK, Guagliumi G, et al. TAXUS VI final 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary lesions. EuroIntervention 2009;4:572-7.
10. Cutlip DE, Windecker S, Mehran R, et al., for the Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
11. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999;100:1872-8. (Pubitemid 29511140)
12. Byrne RA, Iijima R, Mehilli J, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. J Am Coll Cardiol Intv 2009;2:291-9.
13. Park KW, Kim CH, Lee HY, et al. Does "late catch-up" exist in drug-eluting stents: insights from a serial quantitative coronary angiography analysis of sirolimus versus paclitaxel-eluting stents. Am Heart J 2010;159:446-53.e3.
14. Tsuchida K, Serruys PW, Bruining N, et al. Two-year serial coronary angiographic and intravascular ultrasound analysis of in-stent angiographic late lumen loss and ultrasonic neointimal volume from the TAXUS II trial. Am J Cardiol 2007;99:607-15.
15. Claessen BE, Beijk MA, Legrand V, et al. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. Circ Cardiovasc Interv 2009;2:339-47.
16. Raber L. SIRTAX-LATE: Five-Year Clinical and Angiographic Follow-Up From a Prospective Randomized Trial of Sirolimus-Eluting and Paclitaxel-Eluting Stents. Available at: http://www.tctmd.com/txshow.aspx?tid=938640&id= 84110&trid=938634. Accessed December 14, 2010.
17. Kereiakes DJ, Cutlip DE, Applegate RJ, et al. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). J Am Coll Cardiol 2010;56:2084-9.
18. Mahmud E, Ormiston JA, Turco MA, et al. TAXUS Liberte attenuates the risk of restenosis in patients with medically treated diabetes mellitus: results from the TAXUS ATLAS program. J Am Coll Cardiol Intv 2009;2:240-52.
19. Stone GW, Midei M, Newman W, et al., for the SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008;299:1903-13.
20. Stone GW, Rizvi A, Newman W, et al., for the SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362:1663-74.
21. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010;375:201-9.
22. Rupprecht HJ, Espinola-Klein C, Erbel R, et al. Impact of routine angiographic follow-up after angioplasty. Am Heart J 1998;136:613-9. (Pubitemid 28483502)
23. ten Berg JM, Kelder JC, Suttorp MJ, Verheugt FW, Thijs Plokker HW. Influence of planned six-month follow-up angiography on late outcome after percutaneous coronary intervention: a randomized study. J Am Coll Cardiol 2001;38:1061-9.
24. Pinto DS, Stone GW, Ellis SG, et al., for the TAXUS-IV Investigators. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol 2006;48:32-6. (Pubitemid 43929225)
25. Stone GW, Parise H, Witzenbichler B, et al. Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol 2010;56:1597-604.
26. Nakazawa G, Finn AV, Virmani R. Vascular pathology of drug-eluting stents. Herz 2007;32:274-80. (Pubitemid 47049609)
27. Stone GW. HORIZONS-AMI: Three-Year Follow-Up From a Prospective Randomized Trial of Antithrombin Strategies and Drug-Eluting Stents in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty. Available at: http://www.tctmd.com/txshow.aspx?tid=1016264&id=102074&trid=1016256. Accessed December 14, 2010.
28. Weissman NJ, Turco MA, Ormiston JA, et al. Improved strut coverage and less late incomplete apposition with thin-strut TAXUS Liberté vs. TAXUS Express: the importance of stent platform design for drug-eluting stents. Cardiovasc Revasc Med 2010 Dec 2 [E-pub ahead of print].
29. Turco MA, Ormiston JA, Popma JJ, et al. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS program. J Am Coll Cardiol Intv 2008;1:699-709.
30. Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010;160:1035-41.